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Objectives: Bisphosphonates (BPs) might have extra benefits in reducing mortality because of their anti-
atherosclerotic effects, but studies reported conflicting results. We investigated the association between
oral BP use and mortality risk following a major osteoporotic fracture (MOF) in the United Kingdom.
Design: This was a population-based cohort study.
Setting and Participants: In total, 163,273 adults aged 50 years and older with an MOF between 2000 and
2018 from the Clinical Practice Research Datalink in the United Kingdom.
Methods: Cox proportional hazards models were used to estimate the risk of all-cause mortality in
current (0‒6 months), recent (7‒12 months), and past (>1 year) exposures to oral BPs after nonhip MOF
and hip fracture. In addition, stratification by sex, BP type, and duration of follow-up was performed.
Results: Compared with never users of oral BPs, current BP use was associated with a 7% higher all-cause
mortality risk after nonhip MOF, whereas a 28% lower all-cause mortality risk was observed after hip
fracture. Past BP exposure was associated with a 14% and 42% lower risk after nonhip MOF and hip
fracture, respectively. When considering only the first 5 years of follow-up, mortality risk associated with
current BP use was significantly lower for both fracture groups, and the greatest reduction in mortality
risk was observed within the first year. Women had slightly lower risk compared with men.cepts full responsibility for the
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S. Abtahi et al. / JAMDA 21 (2020) 811e816812Conclusions and Implications: We found a slight increased risk of all-cause mortality with current BP
exposure after a nonhip MOF; however, a protective effect was observed following a hip fracture. Both
the timing and the effect size of an association based on the anti-atherosclerotic hypothesis of BPs are not
supported by our results. The decreasing trend of the mortality risk with shorter durations of follow-up
suggests that the observed association is likely due to unknown distortion or unknown pleiotropic
properties of BPs.
 2019 AMDA e The Society for Post-Acute and Long-Term Care Medicine.Major osteoporotic fractures (MOFs) are the main consequence of
osteoporosis, with devastating results for the affected patients,
including a significant increased risk of mortality.1 Occurrence of a hip
fracture markedly increases the risk of subsequent fractures (relative
risks of 2‒7 compared with the general population).2,3 This may
increase mortality after fracture even more.4 Approximately 33% of
men and 22% of women suffering a hip fracture will die within 1 year,
and 51% of men and 39% of women sustaining an MOF will die within
5 years.5e7 But the reasons of this high mortality risk and the ways to
prevent it are still not fully understood.
Secondary fracture prevention with anti-osteoporotic treatment,
such as bisphosphonates (BPs), can prevent subsequent fractures.8,9
Given the strong association between fracture and mortality in older
individuals, it has been hypothesized that use of BPs may lower the
risk of mortality after a fracture. Apart from preventing secondary
fractures, the main underlying potential mechanism that could
explain the mortality-reducing benefits of BPs is protection against
cardiovascular events. This may mostly be the result of lowering lipid
profile and decreasing arterial wall calcification.10e14 However, data
from randomized clinical trials (RCTs) yield conflicting evidence.15,16
Although a post-hoc analysis of the Health Outcomes and Reduced
Incidence with Zoledronic Acid Once Yearly (HORIZON) trial showed a
28% statistically significant mortality reduction among users of zole-
dronic acid after hip fracture,15 the design, analysis, and conduct of
this study have been heavily criticized.17
Because the underlying mechanism for mortality reduction is
likely similar for various BPs, we sought to further test the hypothesis
of an association between all-cause mortality and the initiation of oral
BPs following an MOF in a large representative real-life cohort study.
Thus, the aim of this study was to examine if oral BP treatment was




This was a cohort study using the Clinical Practice Research
Datalink (CPRD; www.cprd.com). The CPRD contains medical records
of 674 practices in the United Kingdom representing approximately
6.9% of the total population.18 Recorded data includes patient de-
mographics, lifestyle parameters, medical history, laboratory test re-
sults, prescription details, specialist referrals, hospital admissions, and
major outcomes since 1987. Previous studies showed a high validity of
using CPRD data regarding MOF.19
Study Population
The study population included all patients aged 50 years and older
with a record of their first fracture between January 1, 2000 and
December 31, 2018. The index date (start of study follow-up) was
defined as the date of first recorded MOF (ie, a fracture of the hip/
femur, vertebrae, humerus, or radius/ulna). We further classified
fractures by hip or nonhip MOF (ie, vertebral, humerus, radius/ulna, orfemur excluding hip). Patients with any fracture prior to age 50 years
and those with use of oral BPs prior to the index date were excluded
(adhering to new-user design). Also, to allow for at least 1 year of
follow-up, we excluded those with an index fracture in 2018.
Exposure and Outcome
The exposure of interest was the use of oral BPs after index date,
which was assessed time-dependently. First, the total follow-up time
for each patient was established by considering the time he/she had
entered the study (ie, index date) and the time follow-up ends, which
could be the end of study period, the date of transfer out of the
practice area, or death (the outcome of interest), whichever came first.
The total follow-up time was then divided into 180-day “periods”
starting from the index date. Exposure status to BPswas defined as the
following: “current exposure”means that the patient has received his
most recent BP prescription during the past 6 months before the start
of a period. “Recent exposure” means that the patient has taken his
most recent BP prescription 7‒12 months before, and “past exposure”
means that the patient has stopped taking BPs for >1 year before.
Using this model, patient exposure is then classified in a dynamic
time-dependent manner, meaning they can move between exposure
groups (current, recent, past) throughout time. However, once a pa-
tient is classified as a current user, he cannot return to the never user
group. The total person-time in each category is accounted for and
contributes to the Cox proportional hazards model. In addition, BP use
was broken down into nitrogen-containing BPs (n-BP, alendronate,
and risedronate) and the non-nitrogen-containing BP (non-n-BP) et-
idronate. The outcome of interest was all-cause mortality as recorded
in the CPRD.
Potential Confounders
Age was considered time dependently, whereas sex, smoking sta-
tus, alcohol use, and body mass index were determined at index date.
A history of the following comorbidities was assessed at the start of
each interval: cerebrovascular disease, chronic kidney disease, chronic
obstructive pulmonary disease, dementia, diabetes mellitus, epilepsy,
heart failure, ischemic heart disease, major infections (sepsis, men-
ingitis, upper and lower respiratory tract infections), or malignant
neoplasms (excluding nonmelanoma skin cancers). In addition, the
use of following medications in the 6 months prior was included:
antihypertensives, anti-Parkinson’s medications, glucocorticoids, loop
diuretics, psychotropic drugs (antipsychotics, anxiolytics, hypnotics,
and sedatives), and statins. Confounders were included in the final
model if they changed the beta coefficient of the association >5% or
based on expert opinion. Collinearity between potential confounders
was assessed.
Statistical Analysis
Cox proportional hazards models were used to assess the risk of
all-cause mortality following fracture associated with current BP use
vs never use (using the SAS PHREG procedure). To avoid immortal
S. Abtahi et al. / JAMDA 21 (2020) 811e816 813time bias, all patient time in each exposure status was incorporated
into the model and all patient time prior to first BP use was defined as
never use. Analyses were stratified by index fracture type (nonhip
MOF vs hip) and sex.
In secondary analyses, current BP exposure was stratified by type
of oral BP (n-BP or non-n-BP). A sensitivity analysis assessed 1-year
and 5-year all-cause mortality risk, censoring the total follow-up
period at 1 or 5 years, respectively.
Data were analyzed using SAS v 9.3 (SAS Institute Inc, Cary, NC).Results
A total of 163,273 patients were included in our cohort with a first
MOF between 2000 and 2018 (Figure 1). Of the eligible fractures,
119,107 (72.9%) were nonhip MOF and 44,166 (27.1%) were hip frac-
tures (Table 1). The mean age of patients with a nonhip MOF and hip
fracturewere 70 and 81 years, respectively. Female patients accounted
for 74% of the nonhip MOF and 69% of hip fracture patients. A similar
pattern of smoking was observed among both fracture groups, with
less than one quarter of patients being current smokers. Frequent
comorbidity and comedication included major infections and anti-
hypertensives. The nonhip MOF comprised 16,378 vertebral fractures
(13.8%), 5294 femur fractures (4.4%), 33,665 humerus fractures
(28.3%), and 63,770 radius/ulna fractures (53.5%). The follow-up time
for BP users was 7.6 years in the nonhip MOF and 5.7 years in the hip
fracture group. The average duration of BP use was 3.3 years among
nonhip MOF patients and 2.7 years among hip fracture patients.
Table 2 shows that current use of oral BPs was associated with a 7%
higher risk of all-cause mortality among patients with an index non-
hip MOF compared with never use (adjusted hazard ratio [HRadj] 1.07,
95% confidence interval [CI] 1.03‒1.10). Mortality risk in the recent
exposure group was also higher compared with the reference group
(HRadj 1.25, 95% CI 1.16‒1.36), but past exposure was associated with
statistically significant lower risk (HRadj 0.86, 95% CI 0.83‒0.90).
Among patients who had sustained a hip fracture, current BP exposure
was associated with a significant 28% lower mortality risk compared
with never BP exposure (HRadj 0.72, 95% CI 0.70‒0.75), whereas recent
and past exposures were associated with 21% and 42% lower risk,
respectively. The HR of past exposurewas statistically lower comparedIneligible paents because of death before 
fracture, and fracture date outside of study 
period, before UTS, or during 2018
n= 7,521
Excluding paents with prior BP use or prior 
fracture (before index date and prior to 
2000)
n= 21,115
Total 50+ paents with a MOF from 
CPRD between 2000-2018 
n= 191,909
Total eligible paents with a 




Fig. 1. Flowchart on establishment of patient population. All patients aged over
50 years from the CPRD in the UK who had a major osteoporotic fracture between
2000 and 2018, and started bisphosphonate use after the (index, first) fracture are
included in the study. 50þ patients, patients aged over 50 years; UTS, up to standard
time of the CPRD practice.with recent and current exposure. In general, mortality risk tended to
be slightly lower among women as compared with men.
Stratifying our analysis by nitrogen-containing BPs showed similar
results to the primary analysis. Analyses with the non-n-BP etidronate
lacked statistical power due to low frequency of exposure (data not
shown).
The 5-year analysis showed a significant reduction in mortality
risk with current BP exposure after nonhip MOF (HRadj 0.91, 95%
CI 0.87‒0.95) compared with never use (Table 3). Following a hip
fracture, all-cause mortality risk associated with current exposure
shifted further from the null value with a significant 39% reduction
compared to never use (HRadj 0.61, 95% CI 0.59‒0.64).
The 1-year mortality risk (data not shown) in the nonhip MOF
group showed a 34% lower risk of all-cause mortality with current BP
exposure (HRadj 0.66, 95% CI 0.60‒0.72), whereas it was not lower with
recent exposure (HRadj 0.23, 95% CI 0.03‒1.61). The 1-year risk of all-
cause mortality among hip fracture patients was considerably lower
for current BP exposure (HRadj 0.41, 95% CI 0.37‒0.44), but not for
recent (HRadj 0.79, 95% CI 0.33‒1.90).
Discussion
This study identified that current oral BP exposure was associated
with a 7% higher all-cause mortality risk after a nonhip MOF and with
a 28% lower mortality risk after a hip fracture. When the follow-up
time was censored at 1 and 5 years, a significant protective effect
was observed in both fracture groups, with a trend away from the null
with decreasing follow-up time: mortality risk with current BP use in
the nonhip MOF group first dropped to a 9% reduction in the 5-year
and then to 34% reduction in the 1-year analysis. In the case of hip
fracture, mortality risk with current BP use first dropped to a 39%
reduction in the 5-year and then to 59% in the 1-year analysis.
Our finding of a higher mortality risk among nonhip MOF pa-
tients with current BP exposure is not in line with findings from 2
meta-analyses of RCTs in 2010 (n ¼ 25,072) and 2018 (n ¼ 63,371),
which showed no association between all-cause mortality and BP
use vs placebo, yielding a pooled relative risk of 0.91 (95% CI 0.80‒
1.03) and 0.95 (95% CI 0.86‒1.04), respectively.20,21 However, the
28% lower mortality risk after hip fracture with current BP exposure
in our study could be in line with those from the HORIZON trial,
which showed a 28% reduced risk of all-cause mortality after
16 months of zoledronic acid use (HR 0.72; 95% CI 0.56‒0.93), and
was included in both meta-analyses.15 However, RCTs have normally
evaluated BP use in individual patients in a time-fixed model, while
we assessed person-time within exposure states in a time-
dependent analysis.
Our results in patients with hip fractures are in line with those
from other observational studies in the field. In a recent cohort study
by van Geel et al, a 21% reduction in mortality risk (HR 0.79, 95% CI
0.64‒0.97) was reported with oral BP use compared to calcium and
vitamin D use among fracture patients.22 Using Danish national health
register data, Bondo et al observed survival benefits for patients who
had taken BP both before and after hip fracture, although their results
may be distorted due to channelling or immortal time bias.23 Sam-
brook et al found 27% mortality reduction for oral BP use compared to
no use in frail older people (mean age¼ 86 years), and an even higher
reduction (80%) in those only after hip fracture, although the number
of BP users were very low (n ¼ 17).24,25
However, BPs are not always found in literature to be beneficial on
mortality risk reduction. Steinbuch et al reported no significant risk
reduction in all-cause mortality for risedronate in patients with a
history of vertebral or hip fracture or with low bone mass, although
there was some benefits in case of stroke and cardiovascular events
reduction.14 In “primary prevention arm” of the HORIZON trial, Black
et al reported a small but not statistically significant increase in death
Table 1
Baseline Characteristics of Participants According to Index Fracture Site
Nonhip MOF Hip Fracture
n % - SD n % - SD
Number of events 119,107 44,166
Follow-up time (y) 6.7 4.8 3.9 4.0
Mean age, y 70.1 11.9 80.5 10.3
Female 88,415 74.2 30,645 69.4
Mean BMI 26.6 5.5 24.3 4.9
Smoking status
Never 70,241 59.0 25,593 57.9
Past 17,856 15.0 6878 15.6
Current 29,056 24.4 9443 21.4
Missing 1954 1.6 2252 5.1
Alcohol use
Yes 80,188 67.3 22,786 51.6
No 28,937 24.3 13,921 31.5
Missing 9982 8.4 7459 16.9
Comorbidities*
Cerebrovascular disease 10,825 9.1 7908 17.9
Chronic kidney disease 11,168 9.4 7850 17.8
COPD 8269 6.9 4198 9.5
Dementia 4395 3.7 6142 13.9
Diabetes mellitus 12,820 10.8 6247 14.1
Epilepsy 3630 3.0 1520 3.4
Heart failure 3284 2.8 2626 5.9
IHD 15,268 12.8 8218 18.6
Major infection 31,928 26.8 10,660 24.1
Malignant neoplasm 14,816 12.4 7568 17.1
Prior fracture 0 0.0 0 0.0
Medicationsy
Antihypertensivesz 49,832 41.8 22,195 50.3
Anti-Parkinson’s 1428 1.2 1325 3.0
BP history 0 0.0 0 0.0
Loop diuretics 13,933 11.7 9790 22.2
Glucocorticoids 5944 5.0 2325 5.3
Psychotropics 16,299 13.7 9580 21.7
Statins 30,354 25.5 11,820 26.8
Fracture at baseline
Hip n/a n/a 44,166 100
Vertebral 16,378 13.8 n/a n/a
Femur 5294 4.4 n/a n/a
Humerus 33,665 28.3 n/a n/a
Radius/ulna 63,770 53.5 n/a n/a
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IHD, ischemic
heart disease; SD, standard deviation.
*Disease comorbidities happened ever before.
yMedications taken 6 months before index fracture.
zExcluding loop diuretics.
S. Abtahi et al. / JAMDA 21 (2020) 811e816814numbers by using zoledronic acid and raised risk of serious atrial-
fibrillation adverse events.16 This might be comparable with our
findings regarding the 7% higher mortality risk with current BP use in
nonhip MOF patients. Although similar results regarding atrial-
fibrillation events have been reported from the Fracture Intervention
Trial by using alendronate, this unconfirmed association has no
apparent biologic plausibility, and we do not expect this happening to
our patients.26
There is some evidence from the literature regarding the anti-
atherosclerotic effects of BPs, such as lowering low-density lipopro-
tein (LDL) cholesterol levels, decreasing arterial wall calcification,
enhancing endothelial nitric oxide production, and reducing mono-
cytes and platelets interactions with epithelial cells.12,13,27e30 If car-
diovascular effects of BPs would be comparable to those of statins,
there should be (indirect) evidence of comparability of the timing
and size of the effect. Large RCTs showed that the statin-induced
reductions of mortality occurred after 11‒24 months of use, which
suggests that the mortality reduction starting after 16 months of BP
use in the HORIZON trial may be plausible.31e34 If we assume this
timing to be true, part of our observations, such as the lowermortalityamong hip fracture patients (with 2.7 years of BP use) might be in line
with the explained anti-atherosclerotic hypothesis of BPs. However,
even among hip fracture patients, we observed the lowest mortality
risk within 1-year analysis, which does not support this hypothesis as
the proper timing has not been met. Also, the expected effect size is
not comparable: large meta-analyses of RCTs comparing statin use
with placebo reported an overall 13% reduction of all-cause mortality,
or 9% mortality reduction per 1.0 mmol/L reduction of LDL choles-
terol.35,36 BPs have been shown to lower LDL in a range from no effect
up to a reduction of approximately 0.34 mmol/L, after 6‒12 months of
use.12,37,38 In the best-case scenario, this would then translate into a 3%
lower risk of all-cause mortality,36 which is around 9 times lower than
the observed 28% reduction in the HORIZON trial and results of our
study in the hip fracture patients.15 Nevertheless, BPs could have
other anti-atherosclerotic effects. A meta-analysis showed BPs have
decreased aortic calcification by 11.2% compared with untreated in-
dividuals,13 and coronary artery calcification is a well-known risk
factor for all-cause mortality.39,40
Although some causal effect of BPs on all-cause mortality cannot
be excluded, it is more likely that unmeasured distortion explains the
largest proportion of the observed risk reductions in the HORIZON
trial and our study. The HORIZON trial was later criticized because of
some inconsistencies regarding the interpretation of data, early
termination of the trial, and the high number of withdrawal or loss to
follow-up.17 Observational studies may have been confounded by se-
lective prescribing of BPs to patients at lower risk of mortality.41
Physicians rarely prescribe oral BPs to very ill and hospitalized pa-
tients. This can culminate in a spurious survival benefit for exposure
drug as the very ill patients are unlikely to receive preventative
medication. Moreover, healthy user and healthy adherer bias could
also play a role.42,43 Previous studies have suggested that patients who
start a preventative medication or who are more adherent are
generally healthier than patients who are not, and therefore may be at
lower risk of mortality.44 These bias scenarios, in addition to the high
mortality rates in the early days after a fracture, could best explain the
lowest HRs with 1-year analysis and the observed decreasing trend of
HRs with shorter durations of follow-up. Moreover, assuming these
bias scenarios, the generally lower HRs among the hip fracture pa-
tients, compared with the nonhip MOF patients, could be partly
explained by longer hospitalization and higher mortality rates after a
hip fracture compared with other MOFs.45 Hip fracture patients are
generally sicker with higher chance of mortality and, hence, are less
likely to receive BPs.
Our study had several strengths. First, we used the CPRD for data
collection, which is one of the world’s largest primary care databases.
Second, as our study period was relatively long (ie, 19 years [2000-
2018]), we could include more than 163,000 patients in the study
cohort, which is by far the largest study sample among observational
studies in this topic. Also, we considered not only hip but all MOFs,
making this the first study to our knowledge to evaluate the mor-
tality after nonhip MOF with BP use. Furthermore, the statistical
analysis was performed time-dependently, which means it incorpo-
rated all person time, avoiding immortal time bias.46 Moreover, we
used different approaches to test the underlying hypothesis of a
causal effect,47 such as assessing the same research question in 2
cohorts with different fracture sites and testing the underlying
pharmacologic hypothesis with analyses that evaluated the onset
and ending of the effect, which the other observational studies did
not do.14,22e25
This study had also some limitations. One objective was to differ-
entiate between n-BP or non-n-BP respecting their effect on mortality
reduction, whichwas not feasible due to low numbers of non-n-BP use
in the United Kingdom. As mentioned above, we could not exclude
those dying shortly after having a fracture, and this could result in
Table 2
Risk of All-Cause Mortality Following an Index Fracture (Nonhip MOF and Hip), Stratified by Fracture Type, Sex, and Oral BP Exposure Status
Events IR per 1000 Pys Age (/Sex) Adjusted Model
HR (95%CI)*
Final Adjusted
Model HR (95% CI)y
Nonhip MOF
BP Never exposurez 21,940 34.6 Reference Reference
BP Past exposure 2341 36.1 0.85 (0.81‒0.89) 0.86 (0.83‒0.90)x
BP Recent exposure 627 57.9 1.40 (1.30‒1.52) 1.25 (1.16‒1.36)x
BP Current exposureǁ 5219 57.4 1.32 (1.28‒1.37) 1.07 (1.03‒1.10)x
Female**
BP Never exposure 14,535 31.4 Reference Reference
BP Past exposure 1933 33.2 0.82 (0.78‒0.86) 0.85 (0.81‒0.89)x
BP Recent exposure 480 50.2 1.30 (1.19‒1.43) 1.19 (1.09‒1.31)x
BP Current exposureǁ 4003 50.1 1.25 (1.21‒1.30) 1.04 (1.01‒1.08)x
Male**
BP Never exposure 7405 43.2 Reference Reference
BP Past exposure 408 61.7 0.93 (0.84‒1.03) 0.88 (0.80‒0.98)x
BP Recent exposure 147 115.1 1.81 (1.53‒2.13) 1.47 (1.25‒1.73)x
BP Current exposureǁ 1216 109.7 1.61 (1.52‒1.72) 1.14 (1.07‒1.21)x
Hip Fracture
BP Never exposurez 16,977 152.3 Reference Reference
BP Past exposure 1440 62.5 0.51 (0.48‒0.53) 0.58 (0.55‒0.62)
BP Recent exposure 398 96.2 0.75 (0.68‒0.83) 0.79 (0.71‒0.87)yy
BP Current exposureǁ 3778 103.5 0.76 (0.73‒0.78) 0.72 (0.70‒0.75)yy
Female**
BP Never exposure 10,942 145.1 Reference Reference
BP Past exposure 1123 59.3 0.50 (0.47‒0.54) 0.58 (0.54‒0.61)x
BP Recent exposure 305 91.8 0.76 (0.68‒0.85) 0.81 (0.72‒0.90)x
BP Current exposureǁ 2738 92.4 0.71 (0.68‒0.74) 0.69 (0.66‒0.72)x
Male**
BP Never exposure 6035 167.5 Reference Reference
BP Past exposure 317 77.0 0.49 (0.43‒0.55) 0.58 (0.52‒0.65)
BP Recent exposure 93 114.5 0.69 (0.56‒0.85) 0.73 (0.59‒0.89)
BP Current exposureǁ 1040 151.2 0.87 (0.81‒0.93) 0.80 (0.75‒0.85)yy
IR, incidence rate; Pys, person years.
*Adjusted only for age where stratified by sex.
yAdjusted for sex, body mass index, smoking status and alcohol use at baseline, and the following variables time dependently: age and use of antihypertensives, anti-
Parkinson’s medications, loop diuretics, glucocorticoids, psychotropics, and statins in the previous 6 months, and history of malignant neoplasm, dementia (for hip fracture
group), and chronic obstructive pulmonary disease (for nonhip MOF group).
zNever exposure denotes to no known use of oral BPs, whereas past, recent, and current exposures refer to taking oral BPs in the time window >12 months, 6‒12 months,
and 0‒6 months prior to the start of a period, respectively.
xHR from each BP exposure status is statistically different from the other exposure status in the same model, by Wald test, P < .05.
ǁNot stratified by nitrogen containing agents because of small cell sizes and reporting restrictions in the CPRD for privacy reasons.
**Patients from each sex are compared only with same sex cohorts.
yyHR is statistically different from the past exposure status, by Wald test, P < .05.
S. Abtahi et al. / JAMDA 21 (2020) 811e816 815distortion (ie, higher estimates of drug effect than what it should be,
especially with shorter durations of follow-up). Moreover, we could
not measure or adjust for healthy user or healthy adherer effect, and
we had no information about the cause of death, socioeconomic statusTable 3
Five-Year Risk of All-Cause Mortality Following an Index Fracture (Nonhip MOF and Hip)
Events IR per 1000 Pys
Nonhip MOF
BP Never exposurey 16,162 42.5
BP Past exposure 753 43.2
BP Recent exposure 342 55.9
BP Current exposure 3135 56.5
Hip Fracture
BP Never exposurey 14,946 183.1
BP Past exposure 644 75.7
BP Recent exposure 279 95.7
BP Current exposure 2831 103.3
IR, incidence rate; Pys, person years.
*Adjusted for sex, body mass index, smoking status and alcohol use at baseline, and
Parkinson’s medications, loop diuretics, glucocorticoids, psychotropics, and statins in the
group), and chronic obstructive pulmonary disease (for nonhip MOF group).
yNever exposure denotes to no known use of oral bisphosphonates, whereas past, rec
>12 months, 6‒12 months, and 0‒6 months prior to the start of a period, respectively.
zHR is statistically different from the past exposure status, by Wald test, P < .05.of patients, or other similar indicators from CPRD. Nonetheless, we
tried to overcome this by running multiple analyses that tested the
same hypothesis indirectly in different ways, taking into account the






0.73 (0.68‒0.79) 0.76 (0.70‒0.82)
1.00 (0.90‒1.12) 0.98 (0.88‒1.09)z
1.03 (0.99‒1.07) 0.91 (0.87‒0.95)z
Reference Reference
0.43 (0.40‒0.47) 0.50 (0.47‒0.55)
0.56 (0.50‒0.64) 0.62 (0.55‒0.70)z
0.60 (0.58‒0.63) 0.61 (0.59‒0.64)z
the following variables time dependently: age and use of antihypertensives, anti-
previous 6 months, and history of: malignant neoplasm, dementia (for hip fracture
ent, and current exposures refer to taking oral bisphosphonates in the time window
S. Abtahi et al. / JAMDA 21 (2020) 811e816816Conclusions and Implications
In conclusion, although we found a higher risk of all-cause mor-
tality with current BP exposure after nonhip MOF, a protective effect
was observed with 1 and 5 years of follow-up. After a hip fracture,
current BP exposure was associated with lower mortality risk in all
analyses. Compared to statin studies and the effect of BPs on LDL
reduction or arterial calcification, both the timing and the effect size
of such an association is not supported by our results. Rather, the
substantially lower mortality risk in the 1-year analysis and the
decreasing trend of HRs with shorter durations of follow-up suggest
that the vast majority of the observed association between BP use and
mortality risk after fracture is explained by unknown distortion or
unknown pleiotropic properties of BPs. We recommend that future
studies focus on evaluation of these hypotheses to elucidate alterna-
tive mechanisms of potential pleiotropic effects of BPs, and on
explaining potential unmeasured distortion.References
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